International Clinical Trial: A 2-part, randomized, double-blind, placebo-controlled study in participants with Duchenne muscular dystrophy amenable to exon 44 skipping to evaluate the safety and efficacy of ENTR-601-44 (ELEVATE-44)

Geneva, May 28 -- International Clinical Trials Registry received information related to the study (ISRCTN15088415) titled 'A 2-part, randomized, double-blind, placebo-controlled study in participants with Duchenne muscular dystrophy amenable to exon 44 skipping to evaluate the safety and efficacy of ENTR-601-44 (ELEVATE-44)' on May 12.

Study Type: Interventional

Study Design: Interventional double blind randomized parallel group placebo controlled trial (Safety, Efficacy)

Primary Sponsor: Entrada Therapeutics, Inc.

Condition: Duchenne muscular dystrophy (DMD) Genetic Diseases

Intervention: Part A Experimental Arm: ENTR-601-44. * Participants will receive a fixed number of doses at one of three dose levels. One dose will be given...